Jingzhou Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jingzhou Zhang has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Edwin K. Silverman
4 shared publicationsJosée Dupuis
Department of Biostatistics, Boston University School of Public Health , Boston, MA
3 shared publications- Michael H. Cho
Brigham and Women's Hospital
3 shared publications - Anica C. Law
The Pulmonary Center, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine , Boston, MA
2 shared publications - Brandon Pang
Boston University School of Medicine Boston, Massachusetts
2 shared publications Brian D. Hobbs
Regeneron Pharmaceutical, Tarrytown, NY, USA
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Elsevier in SSRN Electronic Journal
Proteomic Associations with Fibrosis and Mortality in Interstitial Lung Abnormalities
Background: Interstitial lung abnormalities (ILA) are CT findings that can represent early-stage pulmonary fibrosis. Radiologic features such as definite fibrosis stratify mortality risk; whether blood-based biomarkers can identify high-risk subsets and predict mortality is unknown.Methods: In this longitudinal multicohort study, we used aptamer-based proteomics in four ILA cohorts (COPDGene, AGES-Reykjavik, SPIROMICS, and the Framingham Heart Study) and one idiopathic pulmonary fibrosis (IPF) cohort. Associations were discovered in COPDGene, replicated in meta-analysis of the other ILA cohorts, and separately the IPF cohort. Logistic regression and Cox models identified protein associations with ILA, fibrotic ILA, and mortality; proteins were combined with demographic variables into a multiprotein model to identify fibrosis and predict mortality.Findings: 13,070 participants were included (1198 with ILA, 267 with fibrotic ILA, 100 with IPF). 231 proteins were associated with ILA in COPDGene, of which eight were associated with fibrotic ILA. In the replication cohorts, 200 proteins replicated with ILA, seven with fibrosis, and six with IPF. An eight-protein model improved discrimination of fibrosis (COPDGene area under the curve [AUC]=0·94; replication AUC=0·79; IPF AUC=0·95) and predicted mortality among those with ILA (COPDGene hazard ratio [HR]=2·5, p<0·001; replication HR=1·9, p<0·001), including when stratified by definite radiologic fibrosis.Interpretation: Peripheral blood proteins are associated with ILA, fibrotic ILA, and mortality. An eight-protein model differentiates radiologic fibrosis and predicts mortality, even in those without definite radiologic evidence of fibrosis, supporting the use of blood-based biomarkers to improve risk stratification of these common radiologic findings.Funding: US National Institutes of Health.
- 1 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProteomic Associations with Fibrosis and Mortality in Interstitial Lung Abnormalities
Background: Interstitial lung abnormalities (ILA) are CT findings that can represent early-stage pulmonary fibrosis. Radiologic features such as definite fibrosis stratify mortality risk; whether blood-based biomarkers can identify high-risk subsets and predict mortality is unknown.Methods: In this longitudinal multicohort study, we used aptamer-based proteomics in four ILA cohorts (COPDGene, AGES-Reykjavik, SPIROMICS, and the Framingham Heart Study) and one idiopathic pulmonary fibrosis (IPF) cohort. Associations were discovered in COPDGene, replicated in meta-analysis of the other ILA cohorts, and separately the IPF cohort. Logistic regression and Cox models identified protein associations with ILA, fibrotic ILA, and mortality; proteins were combined with demographic variables into a multiprotein model to identify fibrosis and predict mortality.Findings: 13,070 participants were included (1198 with ILA, 267 with fibrotic ILA, 100 with IPF). 231 proteins were associated with ILA in COPDGene, of which eight were associated with fibrotic ILA. In the replication cohorts, 200 proteins replicated with ILA, seven with fibrosis, and six with IPF. An eight-protein model improved discrimination of fibrosis (COPDGene area under the curve [AUC]=0·94; replication AUC=0·79; IPF AUC=0·95) and predicted mortality among those with ILA (COPDGene hazard ratio [HR]=2·5, p<0·001; replication HR=1·9, p<0·001), including when stratified by definite radiologic fibrosis.Interpretation: Peripheral blood proteins are associated with ILA, fibrotic ILA, and mortality. An eight-protein model differentiates radiologic fibrosis and predicts mortality, even in those without definite radiologic evidence of fibrosis, supporting the use of blood-based biomarkers to improve risk stratification of these common radiologic findings.Funding: US National Institutes of Health.
- 21 February 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (5) , 720-727
Body Mass Index-related genetic factors and COPD imaging phenotypes
Rationale: While low body mass index (BMI) is associated with emphysema and obesity is associated with airway disease in chronic obstructive pulmonary disease (COPD), the underlying mechanisms are unclear. Objectives: To examine the association between BMI-related genetic variants and emphysema and airway disease imaging phenotypes. Methods: We aggregated genetic variants from population-based genome-wide association studies to generate a polygenic score of BMI (PGSBMI). We examined associations of the PGSBMI with automated quantification and visual interpretation of computed tomographic emphysema and airway wall thickness (AWT) in COPD-enriched and community-based cohorts. We summarized the results using meta-analysis. Measurements and main results: In the meta-analyses combining results of all cohorts (n = 16 349), a standard-deviation increase of the PGSBMI was associated with less emphysema as quantified by log-transformed percent of low attenuation areas ≤950 Hounsfield units (β = −0.062, P < .0001) and 15th percentile value of lung density histogram (β = 2.27, P < .0001), and increased AWT as quantified by the square root of wall area of a 10-mm lumen perimeter airway (β = 0.016, P = .0006) and mean segmental bronchial wall area percent (β = 0.26, P = .0013). For imaging characteristics assessed by visual interpretation, a higher PGSBMI was associated with reduced emphysema in both COPD-enriched cohorts (odds ratio [OR] for a higher severity grade = 0.89, P = .0080) and in the community-based Framingham Heart Study (OR for the presence of emphysema = 0.82, P = .0034), and a higher risk of airway wall thickening in the COPDGene study (OR = 1.17, P = .0023). Conclusions: In individuals with and without COPD, a higher BMI polygenic risk is associated with both quantitative and visual decreased emphysema and increased AWT, suggesting genetic determinants of BMI affect both emphysema and airway wall thickening.
- 21 February 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (5) , 720-727
Body Mass Index-related genetic factors and COPD imaging phenotypes
Rationale: While low body mass index (BMI) is associated with emphysema and obesity is associated with airway disease in chronic obstructive pulmonary disease (COPD), the underlying mechanisms are unclear. Objectives: To examine the association between BMI-related genetic variants and emphysema and airway disease imaging phenotypes. Methods: We aggregated genetic variants from population-based genome-wide association studies to generate a polygenic score of BMI (PGSBMI). We examined associations of the PGSBMI with automated quantification and visual interpretation of computed tomographic emphysema and airway wall thickness (AWT) in COPD-enriched and community-based cohorts. We summarized the results using meta-analysis. Measurements and main results: In the meta-analyses combining results of all cohorts (n = 16 349), a standard-deviation increase of the PGSBMI was associated with less emphysema as quantified by log-transformed percent of low attenuation areas ≤950 Hounsfield units (β = −0.062, P < .0001) and 15th percentile value of lung density histogram (β = 2.27, P < .0001), and increased AWT as quantified by the square root of wall area of a 10-mm lumen perimeter airway (β = 0.016, P = .0006) and mean segmental bronchial wall area percent (β = 0.26, P = .0013). For imaging characteristics assessed by visual interpretation, a higher PGSBMI was associated with reduced emphysema in both COPD-enriched cohorts (odds ratio [OR] for a higher severity grade = 0.89, P = .0080) and in the community-based Framingham Heart Study (OR for the presence of emphysema = 0.82, P = .0034), and a higher risk of airway wall thickening in the COPDGene study (OR = 1.17, P = .0023). Conclusions: In individuals with and without COPD, a higher BMI polygenic risk is associated with both quantitative and visual decreased emphysema and increased AWT, suggesting genetic determinants of BMI affect both emphysema and airway wall thickening.
- Open Access
- 6 November 2024
- Published by Elsevier in EBioMedicine
- Vol. 110, 105429
Polygenic and transcriptional risk scores identify chronic obstructive pulmonary disease subtypes in the COPDGene and ECLIPSE cohort studies
- 6 November 2024
- Published by Elsevier in EBioMedicine
- Vol. 110, 105429
Open AccessPolygenic and transcriptional risk scores identify chronic obstructive pulmonary disease subtypes in the COPDGene and ECLIPSE cohort studies
- 1 October 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (7) , 890-899
Genetically Predicted Body Mass Index and Mortality in Chronic Obstructive Pulmonary Disease
Rationale: Body mass index (BMI) is associated with chronic obstructive pulmonary disease (COPD) mortality, but the underlying mechanisms are unclear. The effect of genetic variants aggregated into a polygenic score may elucidate the causal mechanisms and predict risk. Objectives: To examine the associations of genetically predicted BMI with all-cause and cause-specific mortality in COPD. Methods: We developed a polygenic score (PGS) for BMI (PGSBMI) and tested for associations of the PGSBMI with all-cause, respiratory, and cardiovascular mortality in participants with COPD from the COPDGene (Genetic Epidemiology of COPD), ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points), and Framingham Heart studies. We calculated the difference between measured BMI and PGS-predicted BMI (BMIdiff) and categorized participants into groups of discordantly low (BMIdiff 80th percentile) BMI. We applied Cox models, examined potential nonlinear associations of the PGSBMI and BMIdiff with mortality, and summarized results with meta-analysis. Measurements and Main Results: We observed significant nonlinear associations of measured BMI and BMIdiff, but not PGSBMI, with all-cause mortality. In meta-analyses, a one–standard deviation increase in the PGSBMI was associated with an increased hazard for cardiovascular mortality (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.12–1.49), but not for respiratory or all-cause mortality. Compared with participants with concordant measured and genetically predicted BMI, those with discordantly low BMI had higher risks for all-cause mortality (HR, 1.57; 95% CI, 1.41–1.74) and respiratory death (HR, 2.01; 95% CI, 1.61–2.51). Conclusions: In people with COPD, a higher genetically predicted BMI is associated with higher cardiovascular mortality but not respiratory mortality. Individuals with a discordantly low BMI have higher all-cause and respiratory mortality rates than those with a concordant BMI.
- 1 October 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (7) , 890-899
Genetically Predicted Body Mass Index and Mortality in Chronic Obstructive Pulmonary Disease
Rationale: Body mass index (BMI) is associated with chronic obstructive pulmonary disease (COPD) mortality, but the underlying mechanisms are unclear. The effect of genetic variants aggregated into a polygenic score may elucidate the causal mechanisms and predict risk. Objectives: To examine the associations of genetically predicted BMI with all-cause and cause-specific mortality in COPD. Methods: We developed a polygenic score (PGS) for BMI (PGSBMI) and tested for associations of the PGSBMI with all-cause, respiratory, and cardiovascular mortality in participants with COPD from the COPDGene (Genetic Epidemiology of COPD), ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points), and Framingham Heart studies. We calculated the difference between measured BMI and PGS-predicted BMI (BMIdiff) and categorized participants into groups of discordantly low (BMIdiff 80th percentile) BMI. We applied Cox models, examined potential nonlinear associations of the PGSBMI and BMIdiff with mortality, and summarized results with meta-analysis. Measurements and Main Results: We observed significant nonlinear associations of measured BMI and BMIdiff, but not PGSBMI, with all-cause mortality. In meta-analyses, a one–standard deviation increase in the PGSBMI was associated with an increased hazard for cardiovascular mortality (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.12–1.49), but not for respiratory or all-cause mortality. Compared with participants with concordant measured and genetically predicted BMI, those with discordantly low BMI had higher risks for all-cause mortality (HR, 1.57; 95% CI, 1.41–1.74) and respiratory death (HR, 2.01; 95% CI, 1.61–2.51). Conclusions: In people with COPD, a higher genetically predicted BMI is associated with higher cardiovascular mortality but not respiratory mortality. Individuals with a discordantly low BMI have higher all-cause and respiratory mortality rates than those with a concordant BMI.
- Open Access
- 22 June 2024
- Published by Elsevier in CHEST Critical Care
- Vol. 2 (3)
Variation in Triage to Pediatric vs Adult ICUs Among Adolescents and Young Adults With Asthma Exacerbations
- 22 June 2024
- Published by Elsevier in CHEST Critical Care
- Vol. 2 (3)
Open AccessVariation in Triage to Pediatric vs Adult ICUs Among Adolescents and Young Adults With Asthma Exacerbations
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A1130
Genetic Risk for Body Mass and Mortality in COPD
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A1130
Genetic Risk for Body Mass and Mortality in COPD
- 3 February 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (3) , 2101954
A polygenic risk score and age of diagnosis of COPD
Background: Genetic susceptibility may be associated with earlier onset of chronic obstructive pulmonary disease (COPD). We hypothesised that a polygenic risk score (PRS) for COPD would be associated with earlier age of diagnosis of COPD. Methods: In 6647 non-Hispanic White (NHW) and 2464 African American (AA) participants from COPDGene, and 6812 participants from the Framingham Heart Study (FHS), we tested the relationship of the PRS and age of COPD diagnosis. Age at diagnosis was determined by: 1) self-reported age at COPD diagnosis or 2) age at visits when moderate-to-severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 2–4) was observed on spirometry. We used Cox regression to examine the overall and time-dependent effects of the PRS on incident COPD. In the COPDGene study, we also examined the PRS's predictive value for COPD at age e.g. childhood asthma). Results: In Cox models, the PRS demonstrated age-dependent associations with incident COPD, with larger effects at younger ages in both cohorts. The PRS was associated with COPD50 (OR 1.55 (95% CI 1.41–1.71) for NHW, OR 1.23 (95% CI 1.05–1.43) for AA and OR 2.47 (95% CI 2.12–2.88) for FHS participants). In COPDGene, adding the PRS to known early-life risk factors improved prediction of COPD50 in NHW (AUC 0.69 versus 0.74; pversus 0.64; p=0.04) participants. Conclusions: A COPD PRS is associated with earlier age of diagnosis of COPD and retains predictive value when added to known early-life risk factors.
- 3 February 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (3) , 2101954
A polygenic risk score and age of diagnosis of COPD
Background: Genetic susceptibility may be associated with earlier onset of chronic obstructive pulmonary disease (COPD). We hypothesised that a polygenic risk score (PRS) for COPD would be associated with earlier age of diagnosis of COPD. Methods: In 6647 non-Hispanic White (NHW) and 2464 African American (AA) participants from COPDGene, and 6812 participants from the Framingham Heart Study (FHS), we tested the relationship of the PRS and age of COPD diagnosis. Age at diagnosis was determined by: 1) self-reported age at COPD diagnosis or 2) age at visits when moderate-to-severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 2–4) was observed on spirometry. We used Cox regression to examine the overall and time-dependent effects of the PRS on incident COPD. In the COPDGene study, we also examined the PRS's predictive value for COPD at age e.g. childhood asthma). Results: In Cox models, the PRS demonstrated age-dependent associations with incident COPD, with larger effects at younger ages in both cohorts. The PRS was associated with COPD50 (OR 1.55 (95% CI 1.41–1.71) for NHW, OR 1.23 (95% CI 1.05–1.43) for AA and OR 2.47 (95% CI 2.12–2.88) for FHS participants). In COPDGene, adding the PRS to known early-life risk factors improved prediction of COPD50 in NHW (AUC 0.69 versus 0.74; pversus 0.64; p=0.04) participants. Conclusions: A COPD PRS is associated with earlier age of diagnosis of COPD and retains predictive value when added to known early-life risk factors.
- 1 December 2018
- Published by Elsevier in The Journal of Pediatrics
- Vol. 203, 249-258.e5
Comorbidities of Rare Epilepsies: Results from the Rare Epilepsy Network
- 1 December 2018
- Published by Elsevier in The Journal of Pediatrics
- Vol. 203, 249-258.e5
Comorbidities of Rare Epilepsies: Results from the Rare Epilepsy Network
- 5 July 2017
- Published by Wiley in Respirology
- Vol. 22 (8) , 1630-1636
Spirometry reference values for population aged 7–80 years in China
Background and objective: Lung function tests are widely used in clinical and public health practice; however, no valid spirometry reference values were available for the general population in China. This study aimed to provide valid spirometry predictive equations for the general population in China, and to evaluate the predictive performance of previously used equations.Methods: Data from the China National Health Survey 2012–2015 and the ‘Generalized Additive Models for Location, Scale and Shape’ statistical modelling method were used to establish spirometry predictive equations for forced expiratory volume in 1 s (FEV1 ), forced vital capacity (FVC) and FEV1/FVC. Paired t‐tests were used to examine differences between spirometry measurements in this sample and predicted values of four previous spirometry predictive equations.Results: This study included 3130 lifetime non‐smokers (713 males and 2417 females) aged 7–80 years in China. Spirometry predictive equations with age and height as predictive variables plus age‐specific splines were established separately by gender. Most previous spirometry predictive equations were found to significantly overestimate (maximum of 3.69% in FEV1, 1.87% in FVC and 4.19% in FEV1/FVC for males; 11.46% in FEV1, 7.28% in FVC and 3.78% in FEV1/FVC for females) or underestimate (maximum of 5.75% in FEV1 and 8.12% in FVC for males; 7.89% in FEV1 and 9.32% in FVC for females) lung function measurements when applied to this sample population.Conclusion: This study addressed the urgent need for valid and up‐to‐date spirometry reference values for the general population in China. Moreover, previous spirometry predictive equations showed unfavourable generalizability to this sample population.
- 5 July 2017
- Published by Wiley in Respirology
- Vol. 22 (8) , 1630-1636
Spirometry reference values for population aged 7–80 years in China
Background and objective: Lung function tests are widely used in clinical and public health practice; however, no valid spirometry reference values were available for the general population in China. This study aimed to provide valid spirometry predictive equations for the general population in China, and to evaluate the predictive performance of previously used equations.Methods: Data from the China National Health Survey 2012–2015 and the ‘Generalized Additive Models for Location, Scale and Shape’ statistical modelling method were used to establish spirometry predictive equations for forced expiratory volume in 1 s (FEV1 ), forced vital capacity (FVC) and FEV1/FVC. Paired t‐tests were used to examine differences between spirometry measurements in this sample and predicted values of four previous spirometry predictive equations.Results: This study included 3130 lifetime non‐smokers (713 males and 2417 females) aged 7–80 years in China. Spirometry predictive equations with age and height as predictive variables plus age‐specific splines were established separately by gender. Most previous spirometry predictive equations were found to significantly overestimate (maximum of 3.69% in FEV1, 1.87% in FVC and 4.19% in FEV1/FVC for males; 11.46% in FEV1, 7.28% in FVC and 3.78% in FEV1/FVC for females) or underestimate (maximum of 5.75% in FEV1 and 8.12% in FVC for males; 7.89% in FEV1 and 9.32% in FVC for females) lung function measurements when applied to this sample population.Conclusion: This study addressed the urgent need for valid and up‐to‐date spirometry reference values for the general population in China. Moreover, previous spirometry predictive equations showed unfavourable generalizability to this sample population.